News and Press Releases
Infections CF Foundation Invests $3.5 Million in Pulmocide for Development of Novel Antifungal Treatment for Lung Transplant Recipients

The treatment has the potential to prevent Aspergillus fungal infections in people who have had a lung transplant.

Dec. 6, 2021 | 4 min read
Research Cystic Fibrosis Foundation Strikes First-of-Its-Kind Deal With Pioneering Medicines, a Flagship Pioneering Initiative

Foundation to fund up to $110 million for collaboration to accelerate the development of genetic therapies for CF

Nov. 3, 2021 | 4 min read
Coronavirus (COVID-19) CF Foundation Strongly Urges Universal Masking in Schools

The Cystic Fibrosis Foundation supports universal masking in school to protect people with CF and other health conditions against COVID-19.

Aug. 17, 2021 | 2 min read
Our Research Approach | Patient Registry | Research CF Foundation Launches Lung Transplant Biorepository and Patient Registry

The Cystic Fibrosis Lung Transplant Consortium Biorepository and Patient Registry, in collaboration with Cleveland Clinic, will provide critical clinical data and samples to support future research investigating complications of lung transplant.

Aug. 12, 2021 | 4 min read
Get Involved | About the CF Foundation CF Foundation Announces 2021 Impact Grant Recipients

The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants.

July 26, 2021 | 5 min read
About the CF Foundation Cystic Fibrosis Foundation Announces Changes on Board of Trustees

Foundation welcomes new members to advance its mission

July 8, 2021 | 7 min read
Health Care Reform | Advocacy U.S. Supreme Court Rules on the Affordable Care Act

The Cystic Fibrosis Foundation celebrates the decision issued by the United States Supreme Court in California v. Texas, ultimately protecting the Affordable Care Act. 

June 17, 2021 | 3 min read
About the CF Foundation | Our Research Approach CF Foundation Launches New Collaboration to Overcome Challenges to Developing Genetic Therapies for CF

Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.

June 15, 2021 | 4 min read
CFTR Modulators FDA Approves Trikafta for Children Ages 6 Through 11 With Certain Mutations

The U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children ages 6 through 11 who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data.

June 9, 2021 | 4 min read